Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Real-world outcomes and immune-related adverse events in Canadian patients with non-small cell lung cancer receiving neoadjuvant platinum-based chemotherapy and nivolumab.

710 Background: Lung cancer is the leading cause of cancer-related mortality in Canada. Patients with resectable non-small cell lung cancer (NSCLC) can receive curative intent surgery, though relapse rates are high. The addition of nivolumab to neoadjuvant platinum-doublet chemotherapy has recently become the s...

Daniel Wang, S. Moore · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.